News from NYU Langone Health
Morristown Medical Center And NYU Langone Health Expands Partnership To Include Adult Congenital Heart Disease. (WRNJ-AM Hackettstown (NJ))
WRNJ-AM Hackettstown, NJ (3/11) “Two nationally recognized cardiovascular programs in the tri-state region, New Jersey-based Atlantic Health System’s Morristown Medical Center and New York-based NYU Langone Health, are expanding their partnership to provide patients improved access to adult congenital heart disease services and the specialist directed care that will improve patients’ quality of life.” Dan G. Halpern, MD, associate professor, Department of Medicine, the Leon H. Charney Division of Cardiology, program director of NYU Langone Heart’s Adult Congenital Heart Disease (ACHD) Program, the first in the state “to be nationally accredited as an Adult Congenital Heart Disease Comprehensive Care Center and the first in the nation to be re-accredited,” said, “Our partnership with experts at Morristown Medical Center will provide advanced adult congenital heart disease care to patients in New Jersey, allowing them to stay in their local community.”
Wegovy Moves Beyond Weight Loss. (New York Times)
The New York Times (3/11) “While it’s not clear whether the effect of” Wegovy reducing the risk of cardiovascular death “is purely from weight loss, or whether the drug has other heart benefits, the data shows ‘that when you treat obesity seriously in people who have a high burden of disease, you can get really good outcomes,’ Melanie R. Jay, MD, associate professor, Department of Medicine, Division of General Internal Medicine, and Department of Population Health.”
What Popular Fitness Fads Get Wrong. (New York Times)
The New York Times (3/12) “‘The person on social media giving you advice doesn’t have any background in it other than their own anecdotal experience,’ said Heather Milton, MS, clinical exercise physiologist, Department of Rehabilitation Medicine, Sports Performance Center.”
Artificially Sweetened Drinks May Increase AFib Risk By 20%, Study Finds. (Verywell Health)
Verywell Health (3/11) “Drinking artificially sweetened beverages, like Diet Coke or Crystal Light, might increase atrial fibrillation (AFib) risk, according to a new observational study,” with Larry A. Chinitz, MD, the Alvin Benjamin and Kenneth Coyle, Sr. Family Professor of Medicine and Cardiac Electrophysiology, Department of Medicine, the Leon H. Charney Division of Cardiology, commenting, “We know that there are a lot of negative effects associated with artificial sweeteners.”
AI Model Makes Discharge Instructions More Understandable. (WCAV-TV Charlottesville (VA))
WCAV-TV (3/12) “A new study suggests artificial intelligence can transform [discharge instructions] into patient-friendly language,” as “researchers at NYU Langone Health put 50 forms through an AI model; more than 80% became more easily readable.”
Robotic And Navigation TKA Vs Conventional TKA: New Study. (Orthopedics This Week)
Orthopedics This Week (3/11) “According to new research from NYU Langone Health, employing computer-navigated and/or robotic-assist in surgery resulted in better alignment and personalization of implant positioning as well as shorter length of hospital stays,” with co-author Morteza Meftah, MD, associate professor, Department of Orthopedic Surgery, saying, “I think we can now see the use of technology benefits patients, at least in the short-term recovery.”
‘Double Life’ Of Key Immune Protein Reveals New Strategies For Treating Cancer And Autoimmune Diseases. (today news 24)
today news 24 (3/11) “Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect,” according to a new study “led by researchers at NYU Langone Health’s Perlmutter Cancer Center and the University of Oxford.” Study lead investigator and physician-scientist Elliot Philips, MD, PhD, resident, Department of General Internal Medicine, Perlmutter Cancer Center, said, “Our study reveals that the PD-1 receptor functions optimally as dimers driven by interactions within the transmembrane domain on the surface of T cells, contrary to the dogma that PD-1 is a monomer.” Study co-senior investigator and cancer immunologist Jun Wang, PhD, assistant professor, Department of Pathology, Perlmutter Cancer Center, said, “Our findings offer new insights into the molecular workings of the PD-1 immune cell protein that have proven pivotal to the development of the current generation of anticancer immunotherapies, and which are proving essential in the design and developing of the next generation of immunotherapies for autoimmune diseases.” Study co-senior investigator and structural biologist Xiang-Peng Kong, PhD, professor, Department of Biochemistry and Molecular Pharmacology, Perlmutter Cancer Center, said, “Our goal is to use our new knowledge of the functioning of PD-1 to determine if weakening its dimerization, or pairing, helps make anticancer immunotherapies more effective, and just as importantly, to see if strengthening its dimerization helps in the design of agonist drugs that quiet overactive T cells, tamping down the inflammation seen in autoimmune diseases.”
Also reporting is Drug Target Review (UK) (3/11).
Inside NYU Langone’s Films Illustrating A Bold Approach To Health Messaging. (Medical Marketing & Media)
Medical Marketing & Media (3/11) “When it comes to navigating challenges related to communicating about healthcare,” Debbie Cohn, vice president, Department of Marketing and Digital Communications, says, “We are in the most cluttered/congested ad market in the world in New York and we’re also in the most crowded healthcare space,” but NYU Langone Health’s “latest campaign attempts to cut through that clutter with three films: Heart, Home, and Time” that “highlight different aspects of the patient care provided by NYU Langone Health.”
Study Finds 90% Of Tattoo Inks Contain Unlisted Additives, Pigments. (New York Almanack)
New York Almanack (3/11) “In 2013, researchers at NYU Langone Health in New York found that about 6% of people who got a tattoo have experienced tattoo-related rash, severe itching or swelling that has lasted more than four months and for some, many years.”
Nassau Lawmakers OK Legal Work On State Election Changes, New Medical Center. (Newsday (NY))
Newsday (NY) (3/11) reports Nassau lawmakers “voted to hire West Group Law, of White Plains, to handle lease negotiations that include NYU Langone Health, Nassau Community College and the county.” In 2023, NYU Langone Health announced “plans to seek approvals to build a $3 billion medical center on the campus’ grounds.” In a statement, Steve Ritea, senior director, Media Relations, said, “We are actively working with Nassau County, the state and Nassau Community College (NCC) to develop a new, state-of-the-art teaching hospital and medical education and research facility on the NCC campus, further deepening our commitment to providing world-class health care to Long Island residents.”
Second Measles Case Confirmed In Chicago Migrant Shelter. (Fox News)
Fox News (3/11) Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine “joined ‘Fox & Friends’ to discuss his take on rising measles cases, using Botox and filler at a young age and memory concerns stemming from sleep apnea.”
News from NYU Langone Hospital—Long Island
NYU Langone And Tandon Announce Expansion Into Long Island City. (Washington Square (NY) News)
The Washington Square (NY) News (3/11) “NYU will move four health and technology programs to a lab space in Long Island City, Queens after signing a lease for two floors at a recently-completed office building in the area,” including NYU Langone Health moving “three of its programs to the building: the Institute for Systems Genetics, the Tech4Health Institute and the Neuroscience Institute,” as well as “NYU’s Tandon School of Engineering” bringing “its biomedical engineering department to the space.”
